NCT03026348View on ClinicalTrials.gov

Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

April 30, 2017

Study Completion Date

May 18, 2018

Conditions
Respiratory Syncytial Viruses
Interventions
BIOLOGICAL

RSV F Vaccine with Aluminum Phosphate Adjuvant

BIOLOGICAL

RSV F Vaccine

BIOLOGICAL

Matrix-M1 Adjuvant

OTHER

Phosphate Buffer

Trial Locations (5)

3181

Research Site AU006, Prahran

4006

Research Site AU005, Herston

6009

Resarch Site AU001, Nedlands

50000

Research Site AU002, Adelaide

Unknown

Research Site AU004, Sydney

Sponsors

Lead Sponsor

Novavax
All Listed Sponsors
lead

Novavax

INDUSTRY